tbuckley/cabot-search huggingface dataset:
Ponsegromab for the Treatment of Cancer Cachexia
Authors: John D. Groarke, Jeffrey Crawford, Susie M. Collins, Shannon Lubaczewski, Eric J. Roeland, Tateaki Naito, Andrew E. Hendifar, Marie Fallon, Koichi Takayama, Timothy Asmis, Richard F. Dunne, Isik Karahanoglu, Carrie A. Northcott, Magdalena A. Harrington, Michelle Rossulek, Ruolun Qiu, Aditi R. Saxena
Journal: New England Journal of Medicine (2024)

Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer cachexia. In a small, open-label, phase 1b study involving patients with cancer cachexia, ponsegromab, a humanized monoclonal antibody inhibiting GDF-15, was associated with improved weight, appetite, and physical activity, along with suppressed serum GDF-15 levels.
ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer
Authors: T Van Gorp, D Cibula, W Lv, F Backes, F Ortaç, K Hasegawa, K Lindemann, A Savarese, A Laenen, Y M Kim, L Bodnar, M-P Barretina-Ginesta, L Gilbert, B Pothuri, X Chen, M B Flores, T Levy, N Colombo, C Papadimitriou, T Buchanan, L C Hanker, G Eminowicz, L Rob, D Black, J Lichfield, G Lin, R Orlowski, S Keefe, A Lortholary, B Slomovitz
Journal: Annals of Oncology (2024)
Corrigendum to “Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy” [Biomaterials 312 (2025) 122750
Authors: Mostafa Yazdimamaghani, Oleg V Kolupaev, Chaemin Lim, Duhyeong Hwang, Sonia J Laurie, Charles M Perou, Alexander V Kabanov, Jonathan S Serody
Journal: Biomaterials (2024)
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial
Authors: B J Monk, M P Barretina-Ginesta, B Pothuri, I Vergote, W Graybill, M R Mirza, C C McCormick, D Lorusso, R G Moore, G Freyer, R E O'Cearbhaill, F Heitz, D M O'Malley, A Redondo, M S Shahin, C Vulsteke, W H Bradley, C A Haslund, D M Chase, C Pisano, L L Holman, M J Rubio Pérez, P DiSilvestro, L Gaba, T J Herzog, I Bruchim, N Compton, L Shtessel, I A Malinowska, A González-Martín
Journal: Annals of Oncology (2024)
A randomized, double-blind, placebo-controlled phase II study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)
Authors: H Sakai, J Tsurutani, Y Ozaki, H Ishiguro, K Nozawa, T Yamanaka, K Aogi, K Matsumoto, T Iwasa, M Tokiwa, M Tsuneizumi, Y Miyoshi, C Kitagawa, M Yamamoto, Y Takano, C K Imamura, Y Chiba, D Takiguchi, T Ezumi, T Takano
Journal: Annals of Oncology (2024)
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Authors: Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo, Marie Davidian, Butch Tsiatis, Anne M Wallace, A Jo Chien, Erica Stringer-Reasor, Judy C Boughey, Coral Omene, Mariya Rozenblit, Kevin Kalinsky, Anthony D Elias, Christos Vaklavas, Heather Beckwith, Nicole Williams, Mili Arora, Chaitali Nangia, Evanthia T Roussos Torres, Brittani Thomas, Kathy S Albain, Amy S Clark, Carla Falkson, Dawn L Hershman, Claudine Isaacs, Alexandra Thomas, Jennifer Tseng, Amy Sanford, Kay Yeung, Sarah Boles, Yunni Yi Chen, Laura Huppert, Nusrat Jahan, Catherine Parker, Karthik Giridhar, Frederick M Howard, M Michele Blackwood, Tara Sanft, Wen Li, Natsuko Onishi, Adam L Asare, Philip Beineke, Peter Norwood, Lamorna Brown-Swigart, Gillian L Hirst, Jeffrey B Matthews, Brian Moore, W Fraser Symmans, Elissa Price, Diane Heditsian, Barbara LeStage, Jane Perlmutter, Paula Pohlmann, Angela DeMichele, Douglas Yee, Laura J van 't Veer, Nola M Hylton, Laura J Esserman
Journal: Nature Medicine (2024)
Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Authors: Katia Khoury, Jane L Meisel, Christina Yau, Hope S Rugo, Rita Nanda, Marie Davidian, Butch Tsiatis, A Jo Chien, Anne M Wallace, Mili Arora, Mariya Rozenblit, Dawn L Hershman, Alexandra Zimmer, Amy S Clark, Heather Beckwith, Anthony D Elias, Erica Stringer-Reasor, Judy C Boughey, Chaitali Nangia, Christos Vaklavas, Coral Omene, Kathy S Albain, Kevin M Kalinsky, Claudine Isaacs, Jennifer Tseng, Evanthia T Roussos Torres, Brittani Thomas, Alexandra Thomas, Amy Sanford, Ronald Balassanian, Cheryl Ewing, Kay Yeung, Candice Sauder, Tara Sanft, Lajos Pusztai, Meghna S Trivedi, Ashton Outhaythip, Wen Li, Natsuko Onishi, Adam L Asare, Philip Beineke, Peter Norwood, Lamorna Brown-Swigart, Gillian L Hirst, Jeffrey B Matthews, Brian Moore, W Fraser Symmans, Elissa Price, Carolyn Beedle, Jane Perlmutter, Paula Pohlmann, Rebecca A Shatsky, Angela DeMichele, Douglas Yee, Laura J van 't Veer, Nola M Hylton, Laura J Esserman
Journal: Nature Medicine (2024)
Clinical validation of a tissue-agnostic genome-wide methylome enrichment MRD assay for head and neck malignancies
Authors: G Liu, S H Huang, L Ailles, K Rey-McIntyre, C A Melton, S Y Shen, J M Burgener, B Brown, J Zhang, J Min, Y Wang, O Hall, J T Jones, K Budhraja, J B Provance, E V Sosa, A Licon, A Williams, S V Bratman, B A Allen, J Zhang, A-R Hartman, D D De Carvalho
Journal: Annals of Oncology (2024)
The fate of a polygenic phenotype within the genomic landscapes of introgression in the European seabass hybrid zone
Authors: Maeva Leitwein, Ghislain Durif, Emilie Delpuech, Pierre-Alexandre Gagnaire, Bruno Ernande, Marc Vandeputte, Alain Vergnet, Maud Duranton, Frederic Clota, François Allal
Journal: Molecular Biology and Evolution (2024)

Abstract Unraveling the evolutionary mechanisms and consequences of hybridization is a major concern in biology. Many studies have documented the interplay between recombination and selection in modulating the genomic landscape of introgression, but few have considered how associations with phenotype may affect this landscape. Here, we use the European seabass (Dicentrarchus labrax), a key species in marine aquaculture that undergoes natural hybridization, to determine how selection on phenotype modulates the introgression landscape between Atlantic and Mediterranean lineages. We use a high-density single nucleotide polymorphism array to assess individual local ancestry along the genome and improve the mapping of muscle fat content, a polygenic trait that is divergent between lineages. Taking into account variation in recombination rates, we reveal a purging of Atlantic ancestry in the admixed Mediterranean populations. While Atlantic individuals had higher muscle fat content, we observed that genomic regions associated with this trait in Mediterranean populations displayed reduced introgression of Atlantic ancestry. These results emphasize how selection against maladapted alleles shapes the genomic landscape of introgression.
Allostatic Load, Genetic Susceptibility, Incidence Risk, and All-cause Mortality of Colorectal Cancer
Authors: Jianhui Zhao, Erxu Xue, Siyun Zhou, Meng Zhang, Jing Sun, Yuqian Tan, Xue Li
Journal: JNCI Journal of the National Cancer Institute (2024)

Abstract Background Allostatic load (AL) reflects the cumulative burden of chronic stress throughout life, potentially influencing the onset and prognosis of cancer. However, the associations between AL, colorectal cancer (CRC) risk and all-cause mortality in patients with CRC remain unclear. Methods We analyzed the association between AL and CRC risk in 304,959 adults and all-cause mortality in 1,794 patients with CRC from the UK Biobank, using Cox proportional hazards regression models. Results Compared to the AL level in the first quartile, individuals in the second to fourth quartiles had a respective 20%, 29%, and 43% increased risk of CRC; 15%, 24%, and 42% increased risk for colon cancer; and 30%, 38%, and 45% increased risk for rectal cancer. We identified a positive dose-gradient association of AL score with CRC risk, including colon and rectal cancer. Additionally, the association between AL and increased risk of CRC was observed across different strata of genetic susceptibility for CRC. Eliminating AL exposures could prevent nearly 39.24% (95% CI: 36.16-42.32) of CRC incident cases. Meanwhile, a significant association between the AL and all-cause mortality in patients with CRC was found, with a HR of 1.71 (95% CI: 1.16-2.50) for the fourth quartile compared to the AL score in the first quartile, demonstrating a positive dose-response relationship. Conclusion High AL was associated with increased CRC risk and all-cause mortality in CRC patients. Future research should prioritize the development of cognitive or behavioral intervention strategies to mitigate the adverse effects of AL on CRC incidence and prognosis.
Advances and prospects of RNA delivery nanoplatforms for cancer therapy
Authors: Mohamed S Attia, Gregor Kijanka, Nam-Trung Nguyen, Jun Zhang, Hongjie An
Journal: Acta Pharmaceutica Sinica B (2024)

Modern oncology is rapidly evolving, driven by recent advances in RNA-based therapeutics. As new emerging cutting-edge technology, mRNA vaccines hold excellent promise for encoding immunostimulatory molecules, tumor-associated antigens, neoantigens, and chimeric antigen receptors for T-cell reprogramming. RNA interference tools enable highly effective post-transcriptional gene silencing that has rapidly progressed towards more tailored antitumor treatments targeting key molecular players in tumor progression and drug resistance. The inherent challenges and limitations of RNA-based tools, such as size, low stability and surface charges hindering direct cell entry, along with the short circulatory half-life and rapid clearance, call for new and improved RNA delivery systems enabling enhanced gene delivery. Nanoplatforms, particularly certain types of lipid, polymeric nanoparticles and inorganic nanoparticles, provide designed means to address the challenges of RNA delivery and cellular uptake. This paper explores the challenges and barriers while giving insight into the future perspective of RNA-based cancer therapeutics in the context of delivery nanoplatforms and the challenges during development.
Abnormal circadian rhythms exacerbate dilated cardiomyopathy by reducing the ventricular mechanical strength
Authors: Hao Jia, Hao Cui, Zijie Zhao, Han Mo, Ningning Zhang, Yu Zhang, Siyuan Huang, Yue Zhang, Mengda Xu, Lei Han, Yulin Chen, Yuan Chang, Xiumeng Hua, Zhibo Shentu, Tie Xia, Xiao Chen, Jiangping Song
Journal: Cardiovascular Research (2024)

Abstract Aims Dilated cardiomyopathy (DCM) has etiological and pathophysiological heterogeneity. Abnormal circadian rhythm (ACR) is related to the development of DCM in animal models, but exploration based on clinical samples is lacking. Sleep apnea (SA) is the most common disease related to ACR, and we chose SA as the study object to explore ACR-DCM. Methods and results We included a derivation cohort (n =105) and a validation cohort (n = 65). DCM patients were divided into SA and without SA group. RT-qPCR was used to determine the change of rhythm gene expression pattern of heart samples from different timepoints. We used single-nucleus RNA sequencing (snRNA-seq) to explore the abnormal transcriptional patterns in the ACR group, and we verified the findings by pathological staining, atomic force microscopy (AFM), and Rev-erbα/β knockout (KO) mice analysis. DCM patients with SA showed decreased amplitude of rhythm gene expression. SA group showed more severe dilation of left heart chambers. From snRNA-seq, ACR-DCM lost the morning transcriptional patterns, detailly, actin cytoskeleton organization of cardiomyocytes (CMs) disrupted and hypertrophy aggravated, and the proportion of activated fibroblasts (Fibs) decreased with the reduction of fibrotic area ratio. The results of pathological staining, mechanical experiments, and transcriptional feature of Rev-erbα/β KO mice supported the above findings. Conclusion Compared with the non-SA group, left ventricular (LV) wall dilation was more severe and the structural strength was lower in DCM patients with SA, and phenotypic changes in CM and Fib were involved in this process. ACR-DCM was histopathologically characterized by a structurally weak ventricular wall.
The chromosome-level genome provides insights into the evolution and adaptation of extreme aggression
Authors: Peng-Cheng Liu, Zi-Yin Wang, Mei Qi, Hao-Yuan Hu
Journal: Molecular Biology and Evolution (2024)

Abstract Extremely aggressive behavior, as the special pattern, is rare in most species and characteristic as contestants severely injured or killed ending the combat. Current studies of extreme aggression are mainly from the perspectives of behavioral ecology and evolution, while lacked the aspects of molecular evolutionary biology. Here, a high-quality chromosome-level genome of the parasitoid Anastatus disparis was provided, which the males exhibit extreme mate-competition aggression. The integrated multiomics analysis highlighted that neurotransmitter dopamine overexpression, energy metabolism (especially from lipid) and antibacterial activity are likely major aspects of evolutionary formation and adaptation for extreme aggression in A. disparis. Conclusively, our study provided new perspectives for molecular evolutionary studies of extreme aggression as well as a valuable genomic resource in Hymenoptera.
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Jonathan D Spicer, Marina C Garassino, Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gastón L Martinengo, Olivier Bylicki, Delvys Rodríguez-Abreu, Jamie E Chaft, Silvia Novello, Jing Yang, Ashwini Arunachalam, Steven M Keller, Ayman Samkari, Shugeng Gao
Journal: The Lancet (2024)
Preoperative Chemoradiotherapy for Resectable Gastric Cancer
Authors: Trevor Leong, B. Mark Smithers, Michael Michael, Karin Haustermans, Rebecca Wong, Val Gebski, Rachel L. O’Connell, John Zalcberg, Alex Boussioutas, Michael Findlay, David Willis, Alisha Moore, William K. Murray, Florian Lordick, Chris O’Callaghan, Carol Swallow, Gail Darling, Danielle Miller, Andrew Strickland, Moishe Liberman, Laurent Mineur, John Simes
Journal: New England Journal of Medicine (2024)

In Western countries, the current standard of care for resectable gastric cancer is perioperative chemotherapy. Preoperative chemoradiotherapy has been considered, but data are limited regarding this treatment as compared with perioperative chemotherapy alone.
Adipose ADM2 ameliorates NAFLD via promotion of ceramide catabolism
Authors: Pengcheng Wang, Song-Yang Zhang, YongQiang Dong, Guangyi Zeng, Huiying Liu, Xian Wang, Changtao Jiang, Yin Li
Journal: Acta Pharmaceutica Sinica B (2024)

The adipose tissue of mammals represents an important energy-storing and endocrine organ, and its dysfunction is relevant to the onset of several health problems, including non-alcoholic fatty liver disease (NAFLD). However, whether treatments targeting adipose dysfunction could alleviate NAFLD has not been well-studied. Adrenomedullin 2 (ADM2), belonging to the CGRP superfamily, is a protective peptide that has been shown to inhibit adipose dysfunction. To investigate the adipose tissue-specific effects of ADM2 on NAFLD, adipose-specific ADM2-overexpressing transgenic (aADM2-tg) mice were developed. When fed a high-fat diet, aADM2-tg mice displayed decreased hepatic triglyceride accumulation compared to wild-type mice, which was attributable to the inhibition of hepatic
Systemic and dynamic immune landscape of Omicron-infected subjects treated with Lianhua Qingwen capsules
Authors: Shijun Chen, Fuxiang Wang, Yuanlong Lin, Yinyin Xie, Ruihong Zhang, Juan Chen, Niu Qiao, Tong Yin, Yun Tan, Hai Fang, Hongzhou Lu, Zhu Chen, Shanhe Yu, Jiang Zhu, Zhenhua Jia, Saijuan Chen
Journal: Acta Pharmaceutica Sinica B (2024)
Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer
Authors: Yifan Feng, Chengjuan Chen, Anqi Shao, Lei Wu, Haiyu Hu, Tiantai Zhang
Journal: Acta Pharmaceutica Sinica B (2024)

Interleukin-1 receptor-related kinase (IRAK4) is a widely expressed serine/threonine kinase involved in the regulation of innate immunity. IRAK4 plays a pivotal role as a key kinase within the downstream signaling pathway cascades of interleukin-1 receptors (IL-1R) and Toll-like receptors (TLRs). The signaling pathways orchestrated by IRAK4 are integral to inflammatory responses, and its overexpression is implicated in the pathogenesis of inflammatory diseases, autoimmune disorders, and cancer. Consequently, targeting IRAK4-mediated signaling pathways has emerged as a promising therapeutic strategy. Small molecule inhibitors and degraders designed to modulate IRAK4 have shown efficacy in mitigating related diseases. In this paper, we will provide a detailed description of the structure and function of IRAK4, the role of IRAK4 in related diseases, as well as the currently reported small molecule inhibitors and degraders of IRAK4. It is expected to provide new directions for enriching the clinical treatment of inflammation and related diseases.
Pembrolizumab in HER2-Positive Gastric Cancer
Authors: Yelena Y. Janjigian, Akihito Kawazoe, Yuxian Bai, Jianming Xu, Sara Lonardi, Jean Phillipe Metges, Patricio Yañez, Lucjan S. Wyrwicz, Lin Shen, Yuriy Ostapenko, Mehmet Bilici, Hyun Cheol Chung, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Suxia Luo, Mauricio Mahave, Yong Tang, Maeve Lowery, Maria M.F. Monteiro, Linzhi Xu, Chie-Schin Shih, Kanu P. Sharan, Pooja Bhagia, Sun Young Rha
Journal: New England Journal of Medicine (2024)
Next-generation aluminum adjuvants: Immunomodulatory layered double hydroxides NanoAlum reengineered from first-line drugs
Authors: Zhenwei Su, Hamza Boucetta, Jiahui Shao, Jinling Huang, Ran Wang, Aining Shen, Wei He, Zhi Ping Xu, Lingxiao Zhang
Journal: Acta Pharmaceutica Sinica B (2024)

Aluminum adjuvants (Alum), approved by the US Food and Drug Administration, have been extensively used in vaccines containing recombinant antigens, subunits of pathogens, or toxins for almost a century. While Alums typically elicit strong humoral immune responses, their ability to induce cellular and mucosal immunity is limited. As an alternative, layered double hydroxide (LDH), a widely used antacid, has emerged as a novel class of potent nano-aluminum adjuvants (NanoAlum), demonstrating advantageous physicochemical properties, biocompatibility and adjuvanticity in both humoral and cellular immune responses. In this review, we summarize and compare the advantages and disadvantages of Alum and NanoAlum in these properties and their performance as adjuvants. Moreover, we propose the key features for ideal adjuvants and demonstrate that LDH NanoAlum is a promising candidate by summarizing its current progress in immunotherapeutic cancer treatments. Finally, we conclude the review by offering our integrated perspectives about the remaining challenges and future directions for NanoAlum's application in preclinical/clinical settings.
Retrospective analysis of nail findings in the National Registry for Ichthyosis and Related Disorders database
Authors: Kaya L Curtis, Caroline Echeandia-Francis, Julianne M Falotico, Angela Luo, Yuqing Qiu, Chander Grover, Bianca Maria Piraccini, Keith A Choate, Shari R Lipner
Journal: Journal of the American Academy of Dermatology (2024)
Impact of Bisphenol A and its alternatives on oocyte health: a scoping review
Authors: Alexandra E Peters, Emmalee A Ford, Shaun D Roman, Elizabeth G Bromfield, Brett Nixon, Kirsty G Pringle, Jessie M Sutherland
Journal: Human Reproduction Update (2024)

Bisphenol A (BPA) is an endocrine disrupting chemical released from plastic materials, including food packaging and dental sealants, persisting in the environment and ubiquitously contaminating ecosystems and human populations. BPA can elicit an array of damaging health effects and, alarmingly, 'BPA-free' alternatives mirror these harmful effects. Bisphenol exposure can negatively impact female fertility, damaging both the ovary and oocytes therein. Such damage can diminish reproductive capacity, pregnancy success, and offspring health. Despite global government regulations in place to indicate 'safe' BPA exposure levels, these policies have not considered the effects of bisphenols on oocyte health.
Low Genetic Impact of the Roman Occupation of Britain in Rural Communities
Authors: Christiana L Scheib, Ruoyun Hui, Alice K Rose, Eugenia D’Atanasio, Sarah A Inskip, Jenna Dittmar, Craig Cessford, Samuel J Griffith, Anu Solnik, Rob Wiseman, Benjamin Neil, Trish Biers, Sarah-Jane Harknett, Stefania Sasso, Simone A Biagini, Göran Runfeldt, Corinne Duhig, Christopher Evans, Mait Metspalu, Martin J Millett, Tamsin C O’Connell, John E Robb, Toomas Kivisild
Journal: Molecular Biology and Evolution (2024)

The Roman period saw the empire expand across Europe and the Mediterranean, including much of what is today Great Britain. While there is written evidence of high mobility into and out of Britain for administrators, traders, and the military, the impact of imperialism on local, rural population structure, kinship, and mobility is invisible in the textual record. The extent of genetic change that occurred in Britain during the Roman military occupation remains underexplored. Here, using genome-wide data from 52 ancient individuals from eight sites in Cambridgeshire covering the period of Roman occupation, we show low levels of genetic ancestry differentiation between Romano-British sites and indications of larger populations than in the Bronze Age and Neolithic. We find no evidence of long-distance migration from elsewhere in the Empire, though we do find one case of possible temporary mobility within a family unit during the Late Romano-British period. We also show that the present-day patterns of genetic ancestry composition in Britain emerged after the Roman period.
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
Authors: Andrea B. Apolo, Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Parikh, Min Yuen Teo, Randy F. Sweis, Daniel M. Geynisman, Petros Grivas, Gurkamal Chatta, Zachery Roger Reichert, Joseph W. Kim, Mehmet Asim Bilen, Bradley McGregor, Parminder Singh, Abhishek Tripathi, Suzanne Cole, Nicholas Simon, Scot Niglio, Lisa Ley, Lisa Cordes, Sandy Srinivas, Jiaoti Huang, Meagan Odegaard, Colleen Watt, Daniel Petrylak, Jeannie Hoffman-Censits, Yujia Wen, Olwen Hahn, Cecilia Mitchell, Alan Tan, Howard Streicher, Elad Sharon, Helen Moon, Michael Woods, Susan Halabi, Gabriela Perez Burbano, Michael J. Morris, Jonathan E. Rosenberg
Journal: New England Journal of Medicine (2024)

Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown.
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Authors: Aditya Bardia, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H. Barrios, Joyce A. O’Shaughnessy, Hans Wildiers, Jean-Yves Pierga, Qingyuan Zhang, Cristina Saura, Laura Biganzoli, Joohyuk Sohn, Seock-Ah Im, Christelle Lévy, William Jacot, Natasha Begbie, Jun Ke, Gargi Patel, Giuseppe Curigliano
Journal: New England Journal of Medicine (2024)

Outcomes in patients with hormone receptor-positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy.